



# Toward a new Treatment Planning Approach accounting for in-vivo proton range verification

Ludwig-Maximilians-Universität, München  
Liheng Tian



- Proton range uncertainties



- CT number conversion
- Anatomical changes
- Patient set up
- ...






## • In-vivo proton range verification

### • Positron Emission Tomography (PET)

Detection of annihilation photons from the decay of  $\beta^+$ -emitters


1. Takes few tens minutes to use PET scanner
2. Disturbed by organ motion and washout effect







## • In-vivo proton range verification


- Prompt Gamma (PG) Imaging
  - Monitor the Prompt Gamma emitted by nuclear de-excitation of nuclei in the beam path
  - 1. Fast (within nanoseconds)
  - 2. Better PG-dose signal confirmation
  - 3. Higher gamma production rates
  - 4. Clinical experiment shows that the retrieval precision of 2mm can be achieved



# Introduction




Dose delivery




PG emission

# Introduction



- Ideal PG & dose profile



Lateral integration of PG & dose signal


c: Fall-off position  
1/b : Fall-off slope

$$F(x) = a + (1 - a)\text{erf}[b(x - c)]$$

# Introduction



- Ideal PG & dose profile




$$dR = -1.30 \text{ mm}$$


Lateral integration of PG & dose signal

Distance between PG and dose fall-off position:  
 dose: distal 80% dose fall off  
 PG : fitting function

# Introduction




- However, the correlation between PG and dose signal is not always good




Lateral integration of PG & dose signal

# Introduction



- Reason


Tissue inhomogeneity (bone/air in beam path)



Dose delivery


PG emission

# Introduction




- The PG-dose correlation of individual pencil beam (called subPB in the following) is not considered in current treatment planning system (TPS)

# Goal




- Goal of my study:  
Optimize current TPS system, accounting for in-vivo proton range verification to enable a reliable treatment monitoring



## 1. Quantify and identify the degree of 'PG-dose correlation' for each subPBs


Criteria:


- Distance between the Fall-off positions of PG & dose profile (dR)
- Slope of the PG signal Fall-off region ( $1/b$ )
- Fitting quality (Sum of squared errors, SSE)



- Example:


Ideal case:






- Example:

Poor correlation case 1:




Large dR relates to poor correlation directly

A secondary peak, relating to an air cavity, leads to high SSE value



- Example:

Poor correlation case 2:



A shallow slope related also to an air cavity, causing the failure of fitting


# Method




1. Quantify and identify the degree of 'PG-dose correlation' for each subPBs
2. Improve the initial treatment plan while maintaining the quality of plan







# General workflow of CERR TPS and our improved TPS:



# Method



- Boost few subPBs which have the best PG-dose correlation





# Result




- Dose delivery
- PG-dose correlation

# Dose delivery




Patient  
1



# Result







- Dose delivery
- PG-dose correlation




Beam's eye:

The color shows  
the PG-dose  
correlation and

The spot radius is  
linearly proportional  
to the proton  
number






Currently, our new approach is able to:


- Quantify and identify spot-by-spot PG dose correlation automatically in a MC treatment planning process
- Provide the user with candidate subPBs which have reliable PG-dose correlation
- Optimize a treatment plan which is comparable to the initial treatment plan in terms of dose distribution. Besides, few high-intensity subPBs in the new plan could provide reliable in-vivo proton range verification

# Future work



- MC treatment plan is time-consuming, especially when more protons are needed to generate enough PG emission
- Detection devices signal is different from PG emission
- Robustness of PG-dose correlation considering anatomical change and different uncertainties
- Combine state-of-the-art CBCT, DECT

# Conclusion



Though different issues are still needed to be addressed, with the results of this project, the treatment planning process in proton therapy could be improved, by integrating the PG-based in-vivo monitoring of the beam range

This novel approach could lead to a safer and more controllable proton treatment in the future



LUDWIG-  
MAXIMILIANS-  
UNIVERSITÄT  
MÜNCHEN



Thank you!